Journals / Erciyes Medical Journal / 2018 / Cilt: 40 - Sayı: 3

Clinical Course and Follow-Up o Type 1 Pseudohypoaldosteronism

Pages
113–119
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The hook effect and interference probabilities should be considered for evaluating hormone levels.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to evaluate the management of primary pseudohypoaldosteronism type 1 (PHA1), which is a rare disease.
📊
Key Findings & Data:Materials and Methods: We retrospectively reviewed the hospital records of patients who were followed up with a diagnosis of primary PHA1.
💡
Conclusion & Impact:The hook effect and interference probabilities should be considered for evaluating hormone levels.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: This study aimed to evaluate the management of primary pseudohypoaldosteronism type 1 (PHA1), which is a rare disease. Materials and Methods: We retrospectively reviewed the hospital records of patients who were followed up with a diagnosis of primary PHA1. Results: Of the eight patients diagnosed with primary PHA1, two had renal PHA1 and five had systemic PHA1. Five patients were initially administered steroids until a definite diagnosis was made. One patient was initially misdiagnosed with congenital adrenal hyperplasia due to “the high-dose hook effect”. In patients with systemic PHA1, the highest salt requirement was 32–53 mEq/kg/day, which gradually decreased in all patients. Salt supplementation could not be stopped in patients with systemic PHA1 except one patient. Four of the eight patients died. Conclusion: After excluding the causes that may lead to secondary PHA in the initial evaluation of patients referred with a salt-depletion crisis, a differential diagnosis of congenital adrenal hyperplasia and PHA1 should be made. The hook effect and interference probabilities should be considered for evaluating hormone levels.

🔖

Cite This Article

KORKUT, S., AKIN, L., HATİPOĞLU, N., ÖZDEMİR, A., KORKMAZ, L., KENDİRCİ, M., DÜŞÜNSEL, R., GÜNEŞ, T., ÖZTÜRK, M. A., KURTOĞLU, S. (2018). Clinical Course and Follow-Up o Type 1 Pseudohypoaldosteronism. Erciyes Medical Journal, Cilt: 40 - Sayı: 3, 113–119. https://ajindex.com/articles/197377

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Arai K, Chroussos G. Aldosterone deficiency and resistance. Endotext Last update: 04 July 2013 Riepe FG. Pseudohypoaldosteronism. Endocr Dev 2013
  2. [CrossRef] Tajima T, Morikawa S, Nakamura A. Clinical features and molecular basis of pseudohypoaldosteronism type 1. Clin Pediatr Endocrinol 2017
  3. 26(3): 109-17. [CrossRef] Casas-Alba D, Vila Cots J, Monfort Carretero L, Martorell Sampol L, Zennaro MC, Jeunemaitre X, et al. Pseudohypoaldosteronism types I and II: little more than a name in common. J Pediatr Endocrinol Metab 2017
  4. 30(5): 597-601. [CrossRef] Zennaro MC, Hubert EL, Fernandes-Rosa FL. Aldosterone resistance: structural and functional considerations and new perspectives. Mol Cell Endocrinol 2012
  5. 350(2): 206-15. [CrossRef] Amin N, Alvi NS, Barth JH, Field HP, Finlay E, Tverman K, et al. Pseudohypoaldosteronism type 1: clinical features and management in infancy. Endocrinol Diabetes Metab Case Rep 2013
  6. 130010. [CrossRef] Akın L, Kurtoglu S, Kendirci M, Akın MA, Hartmann MF, Wudy SA. Hook effect:A pitfall leading to misdiagnosis of hypoaldosteronism in an infant with pseudohypoaldosteronism. Horm Res Paediatr 2010
  7. 74(1): 72-5. [CrossRef] Ağladıoğlu SY, Aycan Z, Kendirci HNP, Erkek N, Baş VN. Does pseudohypoaldosteronism mask the diagnosis of congenital adrenal hyperplasia? J Clin Res Pediatr Endocrinol 2011
  8. 3(4): 219-21. [CrossRef] Hatta Y, Nakamura A, Hara S, Kamijo T, Iwata J, Hamajima T et al. Clinical and molecular analysis of six Japanese patients with a renal form of pseudohypoaldosteronism type 1. Endocrine Journal 2013
  9. 60(3): 299-304 [CrossRef] Hanukoglu A, Edelheit O, Shriki Y, Gizewska M, Dascal N, Hanukoglu I. Renin-aldosterone response, urinary Na/K ratio and growth in pseudohypoaldosteronism patients with mutations in epithelial sodium channel (ENaC) subunit genes. J Steroid Biochem Mol Biol 2008
  10. 111(3-5): 268-74. [CrossRef] Abraham MB, Larkins N, Choong CS, Shetty VB. Transient pseudohypoaldosteronism in infancy secondary to urinary tract infection. J Paediatr Child Health 2017
  11. 53(5): 458-63 [CrossRef] Pai B, Shaw N, Högler W. Salt-losing crisis in infants-not always of adrenal origin. Eur J Pediatr 2012
  12. 171(2): 317-21. [CrossRef] Amin N, Alvi NS, Barth JH, Field HP, Finlay E, Tyerman K, et al. Pseudohypoaldosteronism type 1: clinical features and management in infancy. Endocrinol Diabetes Metab Case Rep 2013
  13. 130010. [CrossRef] Hanukoglu I, Boggula VR, Vaknine H, Sharma S, Kleyman T, Hanukoglu A. Expression